ArticleEcancermedicalscience2026
Molecular screening for Lynch syndrome in early-onset colorectal cancer in Northern Tanzania.
Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) incidence is increasing in sub-Saharan Africa, with a growing burden of early-onset disease and advanced-stage presentation. The contribution of Lynch syndrome (LS), the most common hereditary cause of CRC, remains poorly defined in this region. We conducted a retrospective pilot study among patients aged ≤50 years diagnosed with CRC in northern Tanzania to determine the prevalence of LS. Tumour samples were initially screened for mismatch repair (MMR) deficiency using immunohistochemistry and microsatellite instability (MSI) testing. Cases demonstrating MMR protein loss underwent MLH1 promoter hypermethylation analysis, and those without hypermethylation were subsequently selected for germline sequencing of MMR genes. Among 47 patients, six (12.8%) had MSI-high tumours and three (6.4%) carried pathogenic germline variants consistent with LS. The observed prevalence is comparable to reports from high-income countries and other African cohorts. These findings demonstrate that LS contributes meaningfully to early-onset CRC in Tanzania and support the need to expand molecular diagnostics and hereditary cancer screening in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.